During 2010, Ranbaxy is targeting a sales of Rs. 7,800 crore as against Rs. 7,340 crore in 2009 — a growth of 6 per cent. It is also aiming to increase net profit by 48 per cent — from Rs. 310 crore to Rs. 460 crore..
Speaking about his India strategy, Ranbaxy Laboratories CEO and managing director Atul Sobti said, “India is 20-25 per cent of our total market and is very profitable. We have rolled out a project Viraat to strengthen market share in rural India and have also commenced the Phase III clinical trials for a new anti-malaria drug in India and Thailand. We will now move into vaccines.”
“Vaccines will be a 2011 play for us,” said Sobti. “We realised various opportunities, while continuing to manage key challenges.”